Financial Performance - For the three months ended March 31, 2024, the total profit and comprehensive income amounted to RMB 19,885,000, compared to RMB 19,198,000 for the same period in 2023, representing an increase of approximately 3.57%[3] - The operating profit for the same period was RMB 25,968,000, up from RMB 23,913,000 in 2023, indicating a growth of about 8.58%[7] - Basic and diluted earnings per share attributable to owners of the company increased to RMB 1.15 from RMB 0.97, reflecting a rise of approximately 18.56%[9] - The pre-tax profit for the period was RMB 24,894,000, compared to RMB 22,309,000 in the previous year, marking an increase of approximately 11.63%[27] Equity and Revenue - The company's total equity as of March 31, 2024, was RMB 1,036,067,000, compared to RMB 1,024,502,000 at the end of the previous quarter, showing a slight increase of about 1.54%[10] - The company's total revenue for the three months ended March 31, 2024, was RMB 280,329,000, down from RMB 299,718,000 in 2023, indicating a decrease of about 6.46%[25] Costs and Expenses - The financial costs decreased to RMB 1,074,000 from RMB 1,604,000, representing a reduction of approximately 33.00%[8] - Income tax expenses increased to RMB 5,009,000 from RMB 3,111,000, which is an increase of about 60.93%[13] Other Income and Non-controlling Interests - The net income attributable to non-controlling interests was RMB 585,000, down from RMB 2,934,000, reflecting a decrease of approximately 80.05%[21] - The company reported a net other income of RMB 2,507,000 for the period, compared to RMB 3,167,000 in the previous year, indicating a decline of about 20.83%[25]

Industry Overview - In 2023, the pharmaceutical industry experienced negative growth due to factors such as the end of the COVID-19 pandemic and centralized procurement policies, leading to a decline in prices of pharmaceutical products and high-value medical consumables [17]. - Sales of pandemic prevention medical devices, hygiene products, biological products, and chemical drugs recorded year-on-year decreases, while sales of Chinese medicines, non-pandemic prevention medical devices, and healthcare products showed an upward trend [17]. - The overall market conditions have prompted the company to adapt its strategies in response to the changing landscape of the pharmaceutical industry [17]. Business Operations - The Group's principal business includes research and development, manufacturing, and selling of medicines and medical devices, as well as the purchase and sales of healthcare food products [21][27][30]. - The Fuzhou Production Base holds 366 approval documents for Chinese and chemical medicines, with 235 varieties included in the National Medical Insurance Catalogue and 146 in the National Essential Drug List [28][31]. - The Beijing Production Base mainly produces chemical medicines and holds 137 approval documents, with 89 products included in the National Medical Insurance Catalogue [28][31]. - The Group has invested in the consistency evaluation of generic medicines and currently owns 35 patents for inventions, with four products having passed consistency evaluation [29][32]. - The Group is focusing on shifting products from low to high gross margins and expanding its consignment and contracted processing business model [21][24]. Financial Performance - The Group's total revenue for the Year was approximately RMB1,064,861,000, representing an increase of approximately 7.92% compared to the previous year [59]. - Approximately RMB576,679,000, accounting for approximately 54.16% of total revenue, was derived from the manufacturing and selling of medicines segment [59]. - Approximately RMB488,182,000, accounting for approximately 45.84% of total revenue, was derived from the sales and distribution of medicines and healthcare products segment [59]. - The Group's gross profit margin decreased to approximately 42%, down from approximately 45% in the previous year, a decline of approximately 3 percentage points [60]. - The Group's gross profit for the Year was approximately RMB447,511,000, representing an increase of approximately 0.76% compared to the previous year [61]. - Profit after tax decreased by approximately 77.24% to approximately RMB14,526,000, while profit attributable to owners decreased by approximately 55.60% to approximately RMB24,127,000 [70][75]. Operational Adjustments - The Group has adjusted its operational strategies in response to market conditions, including expanding the healthcare food product market and increasing the production of fine Chinese medicines [21][24]. - The Group plans to continue optimizing its business structure and improving governance and internal control systems [22][25]. - Neptunus Zhongxin faced challenges with sluggish sales and delayed new product introductions, resulting in a loss-making position, prompting operational adjustments for 2024 [39]. - The company plans to optimize pricing, channel strategies, and enhance budget control to achieve profitability in the upcoming year [41]. Employee and Management - The Group employed a total of 1,444 staff as of December 31, 2023, a decrease from 1,458 in the previous year [103]. - Staff costs, including directors' remuneration, amounted to approximately RMB148,985,000, a slight decrease from approximately RMB151,268,000 in the previous year [104]. - The management team includes experienced individuals with extensive backgrounds in the pharmaceutical industry, contributing to strategic decision-making [115][121][122]. - The company is focused on maintaining competitive employee compensation and benefits, with annual reviews based on performance [108]. - The management emphasizes the importance of employee performance in determining rewards and benefits, aligning with the company's overall business performance [107]. Strategic Focus - The Group aims to stabilize growth while controlling expenses and enhancing gross profit levels through multi-channel marketing and focusing on growth categories [22][25]. - The Group aims to strengthen the promotion of food supplements through a combination of various sales channels to drive sales growth [54]. - The company is actively involved in research and development of new products, leveraging over 30 years of experience in the biochemical and pharmaceutical industries [122]. - The company has a strategic focus on market expansion and enhancing its operational capabilities through experienced leadership [121]. Governance and Compliance - The Board did not recommend the payment of any dividend for the year, consistent with the previous year where no dividend was paid [109]. - The Company has no pre-emptive rights provisions in its articles of association [173]. - The remuneration for directors requires approval from the shareholders' meeting [200]. - The Group's management team includes experienced professionals with extensive backgrounds in finance and the pharmaceutical market [147][148]. Future Outlook - Fuyao Medical plans to introduce new products such as parenteral nutritional supplements in 2024 to broaden its business categories [46]. - The company is actively participating in national procurement alliances to seize market opportunities and drive sales of expiring varieties [36].

Financial Performance - The company's revenue for the year ended December 31, 2023, was RMB 1,064,861,000, representing an increase of 7.9% compared to RMB 986,691,000 in 2022[4] - Gross profit for the same period was RMB 447,511,000, slightly up from RMB 444,142,000, indicating a stable gross margin[4] - Operating profit decreased significantly to RMB 36,248,000 from RMB 89,293,000, reflecting a decline of 59.6% year-on-year[4] - The net profit attributable to the owners of the company was RMB 24,127,000, down from RMB 54,346,000, marking a decrease of 55.7%[4] - Basic and diluted earnings per share fell to RMB 1.44 from RMB 3.24, a decline of 55.6%[4] - The total reportable segment profit for 2023 was RMB 38,419,000, a decrease of 57.1% from RMB 89,599,000 in 2022[48] - The net profit after tax decreased by approximately 77.24%, from RMB 63,830,000 in the previous year to RMB 14,526,000 this year[92] Assets and Liabilities - Total assets as of December 31, 2023, were RMB 1,415,646,000, compared to RMB 1,448,230,000 in 2022, showing a decrease of 2.2%[5] - The total reportable segment assets increased to RMB 1,763,576,000 in 2023 from RMB 1,716,758,000 in 2022, reflecting a growth of 2.7%[48] - The total reportable segment liabilities rose to RMB 718,342,000 in 2023, compared to RMB 678,732,000 in 2022, an increase of 5.8%[48] - Accounts receivable increased to RMB 197,023,000 in 2023 from RMB 177,007,000 in 2022, representing an increase of about 11.3%[65] - The company reported a total of RMB 149,223,000 in accounts payable for 2023, up from RMB 114,003,000 in 2022, which is an increase of approximately 30.9%[68] - The company's current assets net value increased by approximately RMB 72,038,000 to RMB 554,404,000 compared to RMB 482,366,000 at the end of the previous year[95] Cash Flow and Equity - The company's cash and cash equivalents increased to RMB 372,206,000 from RMB 290,098,000, a rise of 28.3%[5] - The total equity attributable to the owners of the company increased to RMB 908,169,000 from RMB 884,042,000, reflecting a growth of 2.7%[6] - The company’s total receivables, including accounts receivable and notes receivable, amounted to RMB 332,954,000 in 2023, compared to RMB 341,968,000 in 2022, showing a slight decrease of about 2.7%[65] Research and Development - The company reported a total of RMB 46,203,000 in R&D expenses for 2023, up from RMB 28,723,000 in 2022, indicating a significant increase of 60.5%[56] - The group has invested in 35 invention patents and has passed consistency evaluations for 4 products, with several others in progress, including Vitamin B6 tablets awaiting approval[77][78] - New drug applications for the self-developed product Sildenafil Citrate orally disintegrating tablets and the sodium bicarbonate injection are expected to receive production approval in 2024[78] Market and Sales - Revenue from pharmaceutical production and sales was RMB 576,679,000, a decrease of 17% from RMB 694,840,000 in 2022[37] - Revenue from the sale and distribution of pharmaceuticals and health products increased to RMB 488,182,000, up 67% from RMB 291,851,000 in 2022[37] - Medical device sales contributed approximately RMB 210,674,000 to total revenue, compared to RMB 113,600,000 in 2022[37] - The Fuzhou subsidiary, Fuyuan Pharmaceutical, has seen significant growth in its medical device sales and plans to introduce new products in 2024 to ensure steady revenue growth[84] Corporate Governance and Compliance - The consolidated financial statements are prepared in accordance with the Hong Kong Financial Reporting Standards and presented in Renminbi (RMB) as the functional currency[12] - The group has adopted new and revised Hong Kong Financial Reporting Standards effective from January 1, 2023, including HKFRS 17 on insurance contracts[15] - The financial statements for the year have been reviewed and confirmed by the audit committee and external auditors, ensuring compliance with applicable accounting standards[132] Employee and Administrative Expenses - Employee costs for the year ended December 31, 2023, amounted to RMB 44,641,000, compared to RMB 47,107,000 in 2022, reflecting a decrease of approximately 3.3%[17] - The company's administrative expenses were approximately RMB 90,433,000, a decrease of about 3.52% from RMB 93,733,000 in the previous year[90] - The company employed a total of 1,444 employees, a decrease from 1,458 employees in the previous year, with employee costs amounting to approximately RMB 148,985,000[108] Shareholder Information - Major shareholder Haiwang Biological held approximately 94.33% of the company's domestic shares, equating to 1,181,000,000 shares[120] - Haiwang Group, the controlling entity, held approximately 98.52% of the company's shares, totaling 1,233,464,500 shares[120] - The board of directors did not recommend any dividends for the current year, consistent with the previous year[110]

Financial Performance - For the nine months ended September 30, 2023, the company's revenue was RMB 823,180,000, representing an increase of 19.4% compared to RMB 689,399,000 for the same period in 2022[8]. - The gross profit for the nine months ended September 30, 2023, was RMB 358,983,000, up 17.9% from RMB 304,560,000 in the previous year[8]. - The profit from operations for the nine months ended September 30, 2023, was RMB 57,936,000, an increase of 11.6% compared to RMB 51,909,000 for the same period in 2022[8]. - For the nine months ended September 30, 2023, the profit before taxation increased to RMB 53,656,000, up 13.9% from RMB 47,335,000 in the same period of 2022[28]. - The total comprehensive income for the period was RMB 14,396,000, down from RMB 16,374,000 in the third quarter of 2022, representing a decline of 12.0%[28]. - The Company’s total comprehensive income for the nine months ended September 30, 2023, was RMB 45,486,000, significantly higher than RMB 34,209,000 in the same period of 2022, marking a growth of 32.9%[28]. - The earnings per share attributable to the owners of the Company for the period was RMB 0.93, unchanged from the same period in 2022[28]. - Profit attributable to the owners of the Company increased by approximately 26.81% from RMB 35,886,000 to RMB 45,506,000[93]. - The Group's net profit after tax was approximately RMB 45,486,000, an increase of about 32.96% compared to approximately RMB 34,209,000 in the previous year[127]. Expenses and Costs - Selling and distribution expenses for the nine months ended September 30, 2023, were RMB 215,651,000, which is an increase of 23.7% from RMB 174,350,000 in the previous year[8]. - Administrative expenses decreased to RMB 60,951,000 for the nine months ended September 30, 2023, down from RMB 64,360,000 in the same period of 2022, reflecting a reduction of 5.7%[8]. - Finance costs for the nine months ended September 30, 2023, were RMB 4,280,000, a decrease of 6.4% compared to RMB 4,574,000 for the same period in 2022[8]. - The Group's financial costs on bank loans decreased from RMB 4,541,000 in 2022 to RMB 4,149,000 in 2023 for the nine-month period, reflecting a reduction of approximately 9%[67]. - Other operating expenses increased by approximately 1.93% to RMB 32,380,000, primarily due to increased impairment on trade receivables[92]. Revenue Sources - Revenue is primarily derived from the production and sale of pharmaceuticals and the distribution of health products[19]. - Revenue from the manufacturing and selling of medicines segment was approximately RMB 591,245,000, accounting for about 71.82% of total revenue, with a year-on-year increase of approximately 21.87%[86]. - Revenue from the sales and distribution of medicines and healthcare products was RMB 231,935,000 for the nine months ended September 30, 2023, up 13.6% from RMB 204,242,000 in the prior year[167]. - The Group's revenue primarily arises from the manufacturing and selling of medicines and healthcare products, with a focus on oncology, cardiovascular, respiratory, digestive, and mental health therapeutic areas[76]. Assets and Equity - The retained earnings as of September 30, 2023, increased to RMB 344,316,000, compared to RMB 298,810,000 at the beginning of the year, reflecting a growth of 15.3%[29]. - The total equity as of September 30, 2023, was RMB 1,047,290,000, an increase from RMB 1,005,304,000 at the beginning of the year[29]. Compliance and Governance - The company is currently assessing the impact of new and amended HKFRSs on its financial results, which are unlikely to have a material impact on the financial statements[17]. - The company has adopted new and amended HKFRSs effective from January 1, 2023, which did not have a significant impact on the financial position[17]. - The company is committed to transparency and compliance with the GEM Listing Rules as part of its corporate governance[163]. - The Company has complied with the Corporate Governance Code during the Reporting Period and aims to enhance its governance standards[141]. Research and Development - Research and development costs for the three months ended September 30, 2023, amounted to RMB 9,144,000, up 16.8% from RMB 7,831,000 in the same period of 2022[41]. - The Group holds a total of 35 patents for inventions, with four products having passed the consistency evaluation[57]. - The Group's pharmaceutical subsidiary has received approval for Doxofylline Injection and Concentrated Sodium Potassium Magnesium Calcium Injection, enhancing its product portfolio[57]. Shareholder Information - The Group's controlling shareholder, Neptunus Bio-engineering, holds approximately 73.51% of the entire issued share capital of the Company, with 70.38% directly held and 3.13% indirectly held through Shenzhen Neptunus Oriental Investment Company Limited[131]. - The weighted average number of ordinary shares in issue for the three-month and nine-month periods ended September 30, 2023, was 1,678,000,000 shares, unchanged from 2022[73]. - The Company has not adopted any share option scheme or granted any options, convertible securities, or warrants as of September 30, 2023[145].

深 圳 市 海 王 英 特 龍 生 物 技 術 股 份 有 限 公 司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* （於中華人民共和國註冊成立之股份有限公司） （股份代號：8329） 截至二零二三年九月三十日止九個月 之第三季度業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所上市的公司帶有 較高投資風險。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方 可作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承受較大的市 場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失 承擔任何責任。 本公告的資料乃遵照聯交所的《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供有關深圳市 海王英特龍生物技術股 ...

Financial Performance - The Group's profit after tax increased from approximately RMB 17,835,000 for the corresponding period of last year to approximately RMB 31,090,000 for the Reporting Period, representing an increase of approximately 74.32%[17] - Profit attributable to the owners of the Company increased from approximately RMB 20,344,000 for the corresponding period of last year to approximately RMB 29,881,000 for the Reporting Period, representing an increase of approximately 46.88%[17] - For the six months ended June 30, 2023, the profit attributable to owners of the Company was approximately RMB29,881,000, compared to RMB20,344,000 for the same period in 2022, representing an increase of 46.8%[80] - Basic earnings per share for the six months ended June 30, 2023, was RMB0.0178, up from RMB0.0121 for the same period in 2022, reflecting a growth of 47.1%[80] - Profit before taxation for the six months ended June 30, 2023, was RMB 36,474,000, up 44.2% from RMB 25,281,000 in the same period of 2022[122] - Profit and total comprehensive income for the period attributable to owners of the company was RMB 29,881,000 for the six months ended June 30, 2023, compared to RMB 20,344,000 in 2022[124] - For the six months ended June 30, 2023, the total comprehensive income was RMB 31,090, an increase from RMB 17,835 for the same period in 2022, representing a growth of 74.5%[128] Revenue and Sales - Revenue for the six months ended June 30, 2023, was RMB 555,531,000, an increase of 26.6% compared to RMB 438,869,000 for the same period in 2022[122] - Revenue from the manufacturing and selling of medicines was RMB 407,492,000, up 31.4% from RMB 310,182,000 year-on-year[160] - The sales and distribution of medicines and healthcare products generated RMB 148,039,000 in revenue, an increase from RMB 128,687,000 in the previous year[160] - For the six months ended June 30, 2023, total revenue reached RMB 555,531,000, a 26.6% increase from RMB 438,869,000 in the same period of 2022[160] - The reportable segment revenue was RMB 602,183,000, an increase from RMB 461,618,000 in the same period of 2022, representing a growth of approximately 30.4%[171] Expenses and Costs - The Group's sales and distribution expenses during the Reporting Period amounted to approximately RMB147,759,000, representing an increase of approximately 36.55% compared to RMB108,208,000 in the same period last year[39] - Other operating expenses totaled approximately RMB24,053,000, reflecting an increase of approximately 15.97% from RMB20,740,000 for the corresponding period of last year, primarily due to higher impairment of inventories and increased research and development expenses[40] - Staff costs, including directors' remuneration, amounted to approximately RMB73,137,000 during the Reporting Period, with salary increases and improved benefits implemented to maintain competitiveness[46] - Administrative expenses for the six months ended June 30, 2023, were RMB 41,207,000, slightly decreased from RMB 41,600,000 in 2022[122] Assets and Liabilities - Trade receivables as of June 30, 2023, amounted to RMB210,517,000, an increase from RMB177,007,000 as of December 31, 2022, representing a growth of 18.9%[82] - The total amount of trade and other receivables as of June 30, 2023, was RMB373,628,000, compared to RMB341,968,000 as of December 31, 2022, reflecting an increase of 9.3%[82] - Net current assets as of June 30, 2023, were RMB 551,898,000, an increase from RMB 482,366,000 at the end of 2022[127] - Total assets less current liabilities as of June 30, 2023, amounted to RMB 1,067,985,000, compared to RMB 1,035,507,000 at the end of 2022[127] - The company's total assets as of June 30, 2023, were RMB 1,036,394, an increase from RMB 962,235 at the end of June 2022, indicating a growth of 7.7%[128] - The total liabilities for reportable segments as of June 30, 2023, were RMB 664,537,000, a slight decrease from RMB 678,732,000 at the end of 2022[195] Inventory and Cash Flow - The Group's inventory write-down for the six months ended 30 June 2023 was RMB 6,013,000, compared to RMB 2,047,000 for the same period in 2022[2] - Inventories as of June 30, 2023, were RMB 222,779, an increase from RMB 203,023 at the end of June 2022, representing a rise of 9.7%[139] - The company reported a net cash used in operating activities of RMB 52,320 for the six months ended June 30, 2023, compared to a net cash generated of RMB 64,462 in the same period of 2022[143] - The company reported a net decrease in cash and cash equivalents of RMB 52,656,000 for the period, compared to an increase of RMB 40,113,000 in the same period last year[145] Research and Development - The Group has developed new medicines such as Doxofylline Injection and Concentrated Sodium Potassium Magnesium Calcium Injection, both of which have obtained approval[10] - The Group's research and development expenses are eligible for a super deduction of 200% for tax purposes, an increase from 175% in the previous year[94] - The group aims to enhance its market presence through ongoing research and development in modern biological technology[148] Corporate Governance - The Company confirmed compliance with Non-Competition Undertakings during the Reporting Period[55] - All Directors confirmed adherence to the "Required Standard of Dealings" and the Company's code of conduct regarding securities transactions[58] - The Company has adopted a code of conduct for securities transactions by Directors that meets the standards set out in the GEM Listing Rules[56] Shareholder Information - As of June 30, 2023, Neptunus Bio-engineering held approximately 73.51% of the entire issued share capital of the Company, with 70.38% directly held and 3.13% indirectly held through Shenzhen Neptunus Oriental Investment Company Limited[49] - Neptunus Group was deemed to be interested in 1,233,464,500 domestic shares of the Company, representing a significant portion of the issued share capital[52] - The Company has not adopted any share option schemes or granted any share options, convertible securities, warrants, or similar rights as of June 30, 2023[50] Taxation - The Group's subsidiaries in the PRC are subject to a preferential enterprise income tax rate of 15% due to their qualification as "High and New Technology Enterprises"[93] - The Group had no assessable profits subject to Hong Kong Profits Tax during the Reporting Period, maintaining a tax provision of zero[96]

深 圳 市 海 王 英 特 龍 生 物 技 術 股 份 有 限 公 司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* （於中華人民共和國註冊成立之股份有限公司） （股份代號：8329） 截至二零二三年六月三十日止六個月 之中期業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於 該等公司的潛在風險，並應經過審慎周詳的考慮後方可作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於聯交所主板買賣之證券承受較大的市場波動風險，同時無法保證在GEM買 賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告的資料乃遵照聯交所的《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供有關深圳市海王英特龍生物技術股份有 ...

Financial Performance - The Company reported a revenue of RMB 299,718,000 for the three months ended March 31, 2023, representing a 38.9% increase compared to RMB 215,698,000 in the same period of 2022[9]. - Gross profit for the reporting period was RMB 140,803,000, up 43.4% from RMB 97,543,000 year-over-year[9]. - Profit before taxation increased to RMB 22,309,000, a 50.1% rise from RMB 14,842,000 in the previous year[10]. - The net profit attributable to the owners of the Company was RMB 16,264,000, compared to RMB 10,541,000 in the same period last year, marking a 54.5% increase[10]. - Basic and diluted earnings per share for the period were RMB 0.97 cents, up from RMB 0.63 cents in the prior year, reflecting a 54% increase[10]. - The Company reported total comprehensive income for the period of RMB 19,198,000, which is a 67.1% increase from RMB 11,508,000 in the previous year[10]. Revenue Breakdown - Revenue from manufacturing and selling medicines was RMB 216,653,000, up 43.7% from RMB 150,703,000 in the previous year[21]. - Revenue from sales and distribution of medicines and healthcare products increased to RMB 83,065,000, a rise of 28.0% from RMB 64,995,000 in 2022[21]. - Other revenue totaled RMB 3,167,000, which is a 40.4% increase from RMB 2,256,000 in the prior year[24]. - The Group's revenue primarily comes from the sale of medicines across various therapeutic areas, including oncology and cardiovascular systems[44][46]. Expenses - Selling and distribution expenses rose to RMB 87,457,000, an increase of 63.6% from RMB 53,440,000 in the previous year[9]. - Administrative expenses remained relatively stable at RMB 22,959,000, compared to RMB 22,364,000 in the same period last year[10]. - Staff costs increased to RMB 38,278,000, reflecting a rise of 2.3% from RMB 37,401,000 in the same period last year[27]. - Research and development costs were RMB 7,319,000, which is an increase of 6.1% compared to RMB 6,897,000 in the previous year[30]. - Other operating expenses amounted to approximately RMB 9,955,000, representing an increase of approximately 20.50% from RMB 8,261,000 for the corresponding period last year[65]. Taxation - Current tax provision for the period was RMB 3,413,000, compared to RMB 3,219,000 in the same period of 2022[34]. - The effective tax rate for the qualified high technology enterprises was 15%, while other subsidiaries were subject to a 25% rate[35]. Equity and Shareholding - The total equity of the Company as of March 31, 2023, was RMB 1,024,502,000, reflecting growth from RMB 955,908,000 at the same time last year[11]. - As of March 31, 2023, Neptunus Bio-engineering holds approximately 73.51% of the entire issued share capital of the Company, with 70.38% directly held and 3.13% indirectly held through Shenzhen Neptunus Oriental Investment Company Limited[81]. - Neptunus Bio-engineering holds 1,181,000,000 domestic shares, representing 94.33% of all domestic shares and 70.38% of the company's issued share capital[92]. Corporate Governance - The Company has established an Audit Committee to review financial statements and provide suggestions to the Board[108]. - The Audit Committee has reviewed the unaudited consolidated results for the Reporting Period[109]. - The Company has complied with the Corporate Governance Code during the Reporting Period[116]. - The roles of the Chairman and General Manager are separate, with Mr. Zhang Feng serving as the current Chairman[110]. - The Company is in the process of identifying a suitable candidate for the General Manager position following the resignation of Mr. Zhou Hang[115]. - The Company is committed to maintaining compliance with GEM Listing Rules[116]. Research and Development - The Group's research and development efforts focus on both independent projects and collaborations with external institutions, emphasizing innovation in generic medicines and new drug development[49][50]. - The Group owns a total of 35 patents for inventions, with four products having passed the consistency evaluation, including Sodium Bicarbonate Tablets and Metformin Hydrochloride Tablets[49][50]. - The Group has received approvals for new products, including Doxofylline Injection and Concentrated Sodium Potassium Magnesium Calcium Injection, enhancing its product portfolio[49][50]. Dividends and Share Options - No dividends were recommended for the reporting period, consistent with the previous year[37][40]. - The Company and its subsidiaries have not adopted any share option scheme or granted any options, convertible securities, or warrants as of March 31, 2023[83]. - During the reporting period, no Directors or supervisors were granted any share options, warrants, or convertible bonds[84].

深 圳 市 海 王 英 特 龍 生 物 技 術 股 份 有 限 公 司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* （於中華人民共和國註冊成立之股份有限公司） （股份代號：8329） 截至二零二三年三月三十一日止三個月的第一季度業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所上市的公司帶有 較高投資風險。有意投資的人士應瞭解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方 可作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣的證券承受較大的市 場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失 承擔任何責任。 本公告乃遵照聯交所的《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供有關深圳市海王英 特龍生物技術股份有限 ...

Business Operations and Market Environment - The Group's business activities resumed rapidly as COVID-19 measures transitioned to a "Class B infection" management, contributing to the overall growth trend of the national economy [16]. - The pharmaceutical industry in China is undergoing significant reforms, including centralized procurement and quality consistency evaluations for generic drugs, which the Group is adapting to [16]. - The Group is focused on enhancing its operational modes in line with key reform arrangements in the pharmaceutical sector [16]. - The Group experienced fluctuating market demand for drugs due to rapid changes in COVID-19 prevention policies, which provided valuable experience in production and supply chain management during epidemic outbreaks [20]. - The Group's pharmaceutical subsidiaries actively participated in drug bidding across various provinces, enhancing market allocation and circulation [35]. Product Development and Sales - The Group's principal activities include research and development, manufacturing, and selling of medicines and healthcare food products, focusing on therapeutic areas such as oncology, cardiovascular, respiratory, digestive, and mental disorders [26]. - By the end of 2022, the Group had 366 Guo Yao Zhun Zi approval documents for Chinese and chemical medicines at its Fuzhou Production Base, with 235 varieties included in the National Medical Insurance Catalogue and 146 in the National Essential Drug List [27]. - The Group has developed various new drugs and exclusive products, including anti-cancer and immune-enhancing medications [31]. - The Group's medicines and healthcare food products division focused on integrated planning and adjusted sales strategies, resulting in a smaller year-on-year revenue decrease compared to the first half of the year [41]. - The Group's sales channels expanded to include direct sales to terminal chain pharmacies, increasing market reach [35]. Financial Performance - The Group's total revenue for the Year was approximately RMB986,691,000, representing an increase of approximately 17.63% compared to the previous year [51]. - Revenue from the manufacturing and selling of medicines segment was approximately RMB694,840,000, accounting for approximately 70.42% of total revenue, with a year-on-year increase of approximately 36.18% [51]. - Revenue from the sales and distribution of medicines and healthcare products segment decreased by approximately 11.18% to approximately RMB291,851,000, accounting for approximately 29.58% of total revenue [51]. - The Group's gross profit margin remained stable at approximately 45%, with gross profit increasing by approximately 18.72% to approximately RMB444,142,000 [52]. - Profit after tax increased by approximately 86.06% to approximately RMB63,830,000, with profit attributable to owners increasing by approximately 51.14% to approximately RMB54,346,000 [60]. Cost Management and Investments - The Group is committed to increasing investment in production and quality assurance systems, as well as in the research and development of new drugs and drug quality consistency evaluation [21]. - The Group has strengthened cost control and marketing efforts for generic and basic drugs, ensuring competitive pricing and availability in the market [20]. - The Group's strategic focus includes cost reduction and efficiency enhancement to achieve stable and high-quality development [36]. - The Group is focused on enhancing core competitiveness and expanding its investment in product manufacturing, quality assurance, and R&D of new medicines [46]. Governance and Management - The Board believes that with continued governance improvements and management efforts, the Group's business will develop positively in the future [21]. - The management team includes experienced professionals with backgrounds in finance and pharmaceuticals [104]. - The Board includes a diverse group of directors with significant industry experience [108]. - The company has a strong board with independent non-executive directors, including Mr. Yick Wing Fat, who has over 30 years of experience in auditing and corporate advisory services [114]. - The appointment of experienced directors is expected to strengthen the company's strategic direction and operational efficiency [119]. Human Resources and Staff Costs - The Group employed a total of 1,458 staff as of December 31, 2022, compared to 1,401 in the previous year [91]. - The Group's total staff costs, including directors' remuneration, amounted to approximately RMB 151,268,000, an increase from approximately RMB 120,083,000 in 2021 [92]. - Administrative expenses rose by approximately 16.39% to approximately RMB93,733,000, mainly due to increased staff costs and expenses related to the acquisition of Neptunus Zhongxin [54]. Future Outlook and Strategic Initiatives - The Group is exploring external investment opportunities in traditional Chinese medicine to bolster future development in this sector [20]. - The company aims to leverage its management's diverse expertise to drive future growth and market expansion [116]. - The company continues to focus on enhancing its market position through strategic investments and partnerships in the pharmaceutical industry [113].